The last 50 years have witnessed the translation of stem cell therapy from the laboratory to the clinic for treating brain disorders, in particular stroke. From the focal stereotaxic transplantation to the minimally invasive intravenous and intraarterial delivery, stem cells display the ability to replenish injured cells and to secrete therapeutic molecules, altogether promoting brain repair. The increased stroke incidence in COVID-19 survivors poses as a new disease indication for cell therapy, owing in part to the cells’ robust anti-inflammatory properties. Optimization of the cell transplant regimen will ensure the safe and effective clinical application of cell therapy in stroke and relevant neurological disorders.

过去 50 年见证了干细胞疗法从实验室转化为临床，用于治疗脑部疾病，尤其是中风。从局部立体定向移植到微创静脉内和动脉内递送，干细胞显示出补充受损细胞和分泌治疗分子的能力，共同促进大脑修复。COVID-19 幸存者中风发病率的增加是细胞治疗的新疾病适应症，部分原因是细胞具有强大的抗炎特性。细胞移植方案的优化将确保细胞治疗在脑卒中及相关神经系统疾病中的安全有效临床应用。